Epix Abandons Anxiety For PDX-00023; Focus Now On Depression

Disappointing Phase III anxiety results lead to change; company eyes candidate as competitor to Forest’s Lexapro.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet